Are you Dr. Wong?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 59 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2946 E Banner Gateway Dr
Gilbert, AZ 85234Phone+1 480-256-6444Fax+1 480-256-4607- Is this information wrong?
Summary
- Dr. Bryan Wong, MD is an oncologist in Gilbert, Arizona. He is currently licensed to practice medicine in Arizona, Nevada, and New York. He is affiliated with Banner Gateway Medical Center.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2005
Tufts Medical CenterResidency, Internal Medicine, 1998 - 2001
Lewis Katz School of Medicine at Temple UniversityClass of 1998
Certifications & Licensure
AZ State Medical License 2009 - 2026
NY State Medical License Active through 2012
NV State Medical License 2005 - 2011
Clinical Trials
- Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Start of enrollment: 2011 Feb 01
- An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- 8 citationsA Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate CancerThai H. Ho, Rafael Nunez-Nateras, Yue Xian Hou, Alan H. Bryce, Donald W. Northfelt, Amylou C. Dueck, Bryan Y. Wong, Melissa L. Stanton, Richard W. Joseph, Erik P. Castle> ;Clinical Genitourinary Cancer. 2017 Apr 1
- 5 citationsPhase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Matthew D. Galsky, Noah M. Hahn, Bryan Wong, Karen M. Lee, Pamela Argiriadi, Costantine Albany, Kiev Gimpel-Tetra, Nancy Lowe, Mohamed Shahin, Vaibhav G. Patel, Che-Ka...> ;Cancer Chemotherapy and Pharmacology. 2015 Oct 13
- 23 citationsPhase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid TumorsGeoffrey I. Shapiro, Raoul Tibes, Michael S. Gordon, Bryan Y. Wong, Joseph Paul Eder, Mitesh J. Borad, David S. Mendelson, Nicholas J. Vogelzang, Bruno R. Bastos, Glen...> ;Clinical Cancer Research. 2011 May 15
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Banner Gateway Medical CenterGilbert, Arizona
